Recon: FDA misses PDUFA goal date for Agios' thalassemia therapy; Mirum to buy Bluejay for up to $820M

• NIH shut out hundreds of young scientists from funding to start their own labs (STAT)
• Driven by GLP-1s, prescription drug spending explodes at major health insurers (STAT)
• FDA misses PDUFA review deadline for Agios' thalassemia drug (Endpoints)
• Kennedy's advisers scrap hepatitis B vaccine guidance for most children in major policy shift (Reuters)
• Why Bill Gates Thinks Donald Trump Cares About Global Health (Bloomberg)

• Congo battles worst cholera outbreak in 25 years, UNICEF says (Reuters)
• Eli Lilly's Mounjaro added to China's state insurance list for diabetes treatment (Reuters)
• Global leaders commit $1.9 billion to eradicate polio amid funding cuts (Reuters)
• Chinese Biotech, Investments Are on Track to Face New US Curbs (Endpoints)
• Carlyle Group Is Said to Lead Bidding for Japan’s Hogy Medical (Bloomberg)
• NICE Rules-Based Pathway Tops Conference Talking Points For UK Healthtechs (MedTech Insight)
• EU Targets Faster, Predictable Multinational Clinical Trial Reviews (Pink Sheet)
• UK-US Trade Deal: How New Value Set For HTAs Will Impact UK Drug Pricing (Pink Sheet)

• Mirum to buy Bluejay for up to $820 million in bet on liver-disease drug (Reuters) (Endpoints)
• Kymera drug positioned to rival Sanofi and Regeneron’s Dupixent succeeds in early-stage eczema trial (STAT)
• Merck outbid three competitors in $9.2B acquisition of Cidara (Endpoints)
• Updated: Structure Therapeutics’ obesity pill stacks up with Novo and Lilly; Ascletis also reports early results (Endpoints)
• BioNTech, OncoC4’s antibody more than halves risk of death in Phase 3 lung cancer trial (Endpoints)
• Kura, Syndax detail data for rival menin inhibitors as both eye earlier use in AML (Endpoints)
• Dyne says Duchenne drug succeeds in pivotal study, heads to FDA for approval (Endpoints)
• Cogent’s mastocytosis drug continues momentum, helps treat sicker patients (Endpoints)
• Recursion Pharma's AI-powered therapy reduces polyp growth in a rare disease trial (Reuters)

• My continuous glucose monitor graphs my life — but misses the big picture (STAT)
• Freenome inks deals to list stock and raise $330M (MedTech Dive)
• FDA advisory panel votes unanimously against J&J heart shunt (MedTech Dive)
• Olympus-backed Swan EndoSurgical names Erik Todd as CEO (MedTech Dive)
• Medtronic’s Hugo RAS Gets FDA Nod For Urologic Procedures, But Intuitive Still Leads, Analyst Says (MedTech Insight)
• Olympus Hits Another Endoscope Snag, Updates Instructions For PolyLoop After 113 Serious Injuries (MedTech Insight)
• CorWave Ready To Dive Into LVAD Market Following First-In-Human Study (MedTech Insight)

• White House to roll out $12 billion farm package (The Hill)

• Tylenol Maker Lacks Texas Business Registration, Judge Says (Bloomberg)
• You Better Move Fast: ACCESS to TEMPO (FDA Law Blog)
• HBV Is Only The Beginning: US CDC’s ACIP Targeting Vaccine Adjuvants Next (Pink Sheet)